​

Amylyx Pharmaceuticals Ownership | Who Owns Amylyx Pharmaceuticals?


OverviewForecastFinancialsChartTranscripts

Amylyx Pharmaceuticals Ownership Summary


Amylyx Pharmaceuticals is owned by 118.94% institutional investors, 6.77% insiders. Fmr is the largest institutional shareholder, holding 17.94% of AMLX shares. Vanguard MStar Total Stk Mkt Idx Invest is the top mutual fund, with 3.03% of its assets in Amylyx Pharmaceuticals shares.

AMLX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAmylyx Pharmaceuticals118.94%6.77%-25.71%
SectorHealthcare Stocks 129.40%12.08%-41.48%
IndustryBiotech Stocks 181.71%11.69%-93.40%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr19.95M17.94%$580.41M
Blackrock funding, inc. /de10.37M9.32%$301.71M
Perceptive advisors8.33M7.54%$149.69M
Vanguard group5.80M6.22%$70.12M
Tcg crossover management6.24M5.65%$112.14M
Janus henderson group4.99M5.27%$69.26M
Commodore capital lp5.65M5.11%$101.47M
Vanguard capital management5.08M4.57%$147.76M
Saturn v capital management4.62M4.18%$83.05M
Blackrock2.67M3.93%$5.07M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Saturn v capital management4.62M11.91%$83.05M
Allostery investments lp120.12K9.81%$769.96K
Commodore capital lp5.65M6.04%$101.47M
Almitas capital974.88K4.20%$17.51M
Aldebaran capital196.03K4.10%$5.70M
Ally bridge group (ny)437.39K3.62%$5.94M
First light asset management3.02M3.30%$54.30M
Tcg crossover management6.24M2.70%$112.14M
Great point partners700.00K2.38%$12.57M
Perceptive advisors8.33M2.25%$149.69M

Top Buyers

HolderShares% AssetsChange
Fmr19.95M0.03%3.22M
Paradigm biocapital advisors lp1.90M0.73%1.90M
Jpmorgan chase3.43M0.01%1.57M
Blackrock funding, inc. /de10.37M0.00%1.54M
Alyeska investment group1.05M0.05%1.05M

Top Sellers

HolderShares% AssetsChange
Blackrock2.67M0.00%-1.80M
Adage capital partners gp1.90M0.05%-1.66M
Boxer capital---1.50M
Eventide asset management---1.33M
Farallon capital management---1.15M

New Positions

HolderShares% AssetsChangeValue
Paradigm biocapital advisors lp1.90M0.73%1.90M$25.82M
Alyeska investment group1.05M0.05%1.05M$18.91M
Braidwell lp612.84K0.25%612.84K$8.33M
Ally bridge group (ny)437.39K3.62%437.39K$5.94M
Nearwater capital markets425.00K0.13%425.00K$7.63M

Sold Out

HolderChange
Ifp advisors-1.00
Ameritas advisory services-3.00
Nelson, van denburg & campbell wealth management group-10.00
Financial consulate-25.00
Kelly financial services-33.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20262438.97%132,251,99014.29%1181.09%17340.65%45-27.42%
Jun 30, 202622021.55%115,598,6831.27%1040.98%12335.16%599.26%
Mar 31, 202667-64.74%11,342,671-89.90%110.08%27-75.23%25-46.81%
Dec 31, 2025114-35.23%37,817,895-65.53%400.27%65-38.10%25-46.81%
Sep 30, 202517034.92%109,563,43439.61%1221.59%10146.38%4643.75%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard MStar Total Stk Mkt Idx Invest3.80M3.03%12.11K
Vanguard Total Stock Mkt Idx Inv3.15M2.84%36.90K
Vanguard Morn Total Stk Mkt Idx Investor3.15M2.84%36.90K
iShares Russell 2000 ETF2.63M2.05%-
Fidelity Advisor Biotechnology I2.43M1.89%-
Fidelity Small Cap Growth2.12M1.65%-
Franklin Biotechnology Discv A(acc)USD1.72M1.37%-
Strategic Advisers Fidelity US TtlStk1.70M1.32%384.65K
Fidelity Select Health Care1.60M1.27%180.00K
Fidelity Select Biotechnology1.47M1.17%372.94K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 09, 2026FRATES JAMES M Chief Financial OfficerSell$370.36K
Nov 09, 2026FRATES JAMES M Chief Financial OfficerSell$226.29K
Nov 10, 2026FRATES JAMES M Chief Financial OfficerSell$222.98K
Nov 10, 2026FRATES JAMES M Chief Financial OfficerSell$388.11K
Nov 09, 2026Klee Justin B. Co-Chief Executive OfficerSell$1.10M

Insider Transactions Trends


DateBuySell
2026 Q4-9
2026 Q3-12
2026 Q21-
2026 Q1-17
2025 Q411

AMLX Ownership FAQ


Who Owns Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals shareholders are primarily institutional investors at 118.94%, followed by 6.77% insiders and -25.71% retail investors. The average institutional ownership in Amylyx Pharmaceuticals's industry, Biotech Stocks , is 181.71%, which Amylyx Pharmaceuticals falls below.

Who owns the most shares of Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals’s largest shareholders are Fmr (19.95M shares, 17.94%), Blackrock funding, inc. /de (10.37M shares, 9.32%), and Perceptive advisors (8.33M shares, 7.54%). Together, they hold 34.80% of Amylyx Pharmaceuticals’s total shares outstanding.

Does Blackrock own Amylyx Pharmaceuticals?

Yes, BlackRock owns 3.93% of Amylyx Pharmaceuticals, totaling 2.67M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 5.07M$. In the last quarter, BlackRock decreased its holdings by -1.805M shares, a -40.34% change.

Who is Amylyx Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Saturn v capital management is Amylyx Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 11.91% of its assets in 4.62M Amylyx Pharmaceuticals shares, valued at 83.05M$.

Who is the top mutual fund holder of Amylyx Pharmaceuticals shares?

Vanguard MStar Total Stk Mkt Idx Invest is the top mutual fund holder of Amylyx Pharmaceuticals shares, with 3.03% of its total shares outstanding invested in 3.8M Amylyx Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools